FY26 Results: Key Subsidiary Innoxel Secures USFDA & EU-GMP Approval, Paving Way for US/EU Launch
Bharat Parenterals Ltd · 541096 · BSE ·
**Major Regulatory Win:** Subsidiary Innoxel Lifesciences received USFDA and EU-GMP approvals with zero major observations, a transformative event unlocking entry into US & European markets. **Financials:** Consolidated FY26 Revenue grew 1.5% to ₹345.4 Cr. However, the group repo…